N-adamantyl-N'-cyclohexyl urea | 13074-28-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: N-adamantyl-N'-cyclohexyl urea
• 英文别名: ACU；N-(1-Adamantyl)-N'-cyclohexylharnstoff；N-adamantyl-N'-cyclohexylurea；1-(1-adamantyl)-3-cyclohexylurea
• CAS: 13074-28-7
• 化学式: C₁₇H₂₈N₂O
• mdl: MFCD00194717
• 分子量: 276.422
• InChiKey: VESXWSWSGQONHC-UHFFFAOYSA-N

物化性质

• 熔点：
  251-252 °C(Solv: ethanol (64-17-5))
• 沸点：
  460.5±12.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  金刚烷胺 、 环己基异氰酸酯 以 正己烷 为溶剂， 以90%的产率得到N-adamantyl-N'-cyclohexyl urea
  参考文献：
  名称：

  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases

  摘要：

  The soluble epoxide hydrolase (sEH) is involved in the metabolism of arachidonic, linoleic, and other fatty acid epoxides, endogenous chemical mediators that play an important role in blood pressure regulation and inflammation. 1,3-Disubstituted ureas, carbamates, and amides are new potent and stable inhibitors of sEH. However, the poor solubility of the lead compounds limits their use. Inhibitor structure-activity relationships were investigated to better define the structural requirements for inhibition and to identify points in the molecular topography that could accept polar groups without diminishing inhibition potency. Results indicate that lipophilicity is an important factor controlling inhibitor potency. Polar groups could be incorporated into one of the alkyl groups without loss of activity if they were placed at a sufficient distance from the urea function. The resulting compounds had a 2-fold higher water solubility. These findings will facilitate the rational design and optimization of sEH inhibitors with better physical properties. (C) 2002 Published by Elsevier Science Inc.

  DOI：

  10.1016/s0006-2952(02)00952-8

文献信息

• Inhibitors for the soluble epoxide hydrolase
  申请人：Hammock D. Bruce

  公开号：US20050164951A1

  公开（公告）日：2005-07-28

  Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

  提供了抑制可溶性环氧化酶（sEH）的抑制剂，这些抑制剂结合了多个药效团，在治疗疾病方面非常有用。
• METHODS OF TREATING AVIAN HYPERTENSION
  申请人：Hammock Bruce D.

  公开号：US20080188554A1

  公开（公告）日：2008-08-07

  The present invention provides methods of treating avian pulmonary hypertension syndrome by administering to an avian subject a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase (“sEHI”), alone or co-administered in combination with a cis-epoxyeicosantrienoic acid (“EET”). The invention also provides nucleic acid and amino acid sequences of an avian soluble epoxide hydrolase.

  本发明提供了治疗禽类肺高血压综合症的方法，通过向禽类主体投与可治疗量的可溶性环氧酶抑制剂（“sEHI”），单独或联合使用顺式环氧二十碳三烯酸（“EET”）。本发明还提供了禽类可溶性环氧酶的核酸和氨基酸序列。
• INHIBITORS FOR THE SOLUBLE EPOXIDE HYDROLASE
  申请人：Hammock Bruce D.

  公开号：US20090326039A1

  公开（公告）日：2009-12-31

  Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

  提供了可用于治疗疾病的可溶性环氧水解酶（sEH）的抑制剂，其中包含多个药效团。
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION
  申请人：Hammock D. Bruce

  公开号：US20070117782A1

  公开（公告）日：2007-05-24

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

  本发明提供了一些化合物，用于治疗高血压的治疗应用中，抑制环氧水解酶。实施本发明的优选化合物类别具有由式1所示的结构，其中Z为氧或硫，W为碳、磷或硫，X和Y各自独立地为氮、氧或硫，而X还可以是碳，R1-R4中至少有一个是氢，当X为氮时，R2为氢，但当X为硫或氧时，R2不存在，当Y为氮时，R4为氢，但当Y为硫或氧时，R4不存在，而R1和R3各自独立地为C1-C20取代或未取代的烷基、环烷基、芳基、酰基或杂环基。
• USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES
  申请人：Wang Yi-Xin

  公开号：US20100063583A1

  公开（公告）日：2010-03-11

  Disclosed herein are compositions and methods for treating inflammatory vascular diseases. Examples of inflammatory vascular disease include, but are not limited to, in-stent stenosis, coronary arterial diseases (CAD), angina, acute myocardial infarction, acute coronary syndrome, chronic heart failure (CHF), peripheral arterial occlusive diseases (PAOD), critical limb ischemia (CLI), cardiac, kidney, liver and intestinal ischemia, renal failure, cardiac hypertrophy, atherosclerosis, abdominal aortic aneurysm, vasculitis, carotid artery stenosis.

  本文公开了治疗炎症性血管疾病的组合物和方法。炎症性血管疾病的例子包括但不限于支架内狭窄、冠状动脉疾病（CAD）、心绞痛、急性心肌梗死、急性冠状动脉综合症、慢性心力衰竭（CHF）、周围动脉闭塞性疾病（PAOD）、严重肢体缺血（CLI）、心脏、肾脏、肝脏和肠道缺血、肾功能衰竭、心肌肥大、动脉粥样硬化、腹主动脉瘤、血管炎、颈动脉狭窄等。